Lesion of sciatic nerve

Summary

Lesion of sciatic nerve (MONDO:0001543) is a disease. A subtype of lumbosacral plexus lesion — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lesion of sciatic nerve
Mondo ID	MONDO:0001543
DOID	DOID:12528
ICD-10-CM	G57.0
ICD-11	1358497313
SNOMED CT	367137004
UMLS	C0154748
MedGen	56346
GARD	0022965
Anatomy (UBERON)	UBERON:0001322
Is cancer (heuristic)	no

Also known as: peripheral nerve lesion of sciatic nerve · sciatic nerve peripheral nerve lesion

Disease family

This is a subtype of lumbosacral plexus lesion. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › nerve plexus disorder › lumbosacral plexus lesion › lesion of sciatic nerve

Related subtypes (2): lumbar plexus neoplasm, sacral nerve plexus disorder

Subtypes (2): plantar nerve lesion, common peroneal nerve lesion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.